Under the terms of the agreement, Samaritan will grant CHDI an 18-month non-exclusive license to evaluate the usefulness of six of Samaritan’s Alzheimer’s drugs, SP-233, Sp-sc4, Sp-sc7, Sp-04, Sp-04m, and Sp-08, as possible therapeutics for Huntington’s disease (HD). CHDI will pay for the cost of this evaluation and Samaritan will retain all rights in its compounds.
Janet Greeson, CEO of Samaritan, said: “We believe our central nervous system (CNS) drugs hold a lot of promise to cognitively improve Alzheimer’s patients and protect their brain from further damage, so we are extremely hopeful our drugs will demonstrate and hold the same promise for Huntington’s disease.”